US regulatory status: approved.
pharma · MASH · MASLD · SGMT
Sagimet Biosciences
Sagimet Biosciences drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
155 Bovet Rd, Suite 303, San Mateo, California 94402, US HQ
27 Employees
Public company Type
SGMT · NYSE Ticker
Company details
- Status
- Public
- HQ
- 155 Bovet Rd, Suite 303, San Mateo, California 94402, US
- Employees
- 27
- Programs
- 12
- Drugs
- 4
- Patents
- 1
Sagimet Biosciences pipeline
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Sagimet Biosciences drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
-
Development asset linked to Sagimet Biosciences in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent